Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr 1;79(7):516-25.
doi: 10.1016/j.biopsych.2015.07.028. Epub 2015 Oct 30.

An Introduction to the Endogenous Cannabinoid System

Affiliations
Review

An Introduction to the Endogenous Cannabinoid System

Hui-Chen Lu et al. Biol Psychiatry. .

Abstract

The endocannabinoid system (ECS) is a widespread neuromodulatory system that plays important roles in central nervous system development, synaptic plasticity, and the response to endogenous and environmental insults. The ECS comprises cannabinoid receptors, endogenous cannabinoids (endocannabinoids), and the enzymes responsible for the synthesis and degradation of the endocannabinoids. The most abundant cannabinoid receptors are the CB1 cannabinoid receptors; however, CB2 cannabinoid receptors, transient receptor potential channels, and peroxisome proliferator activated receptors are also engaged by some cannabinoids. Exogenous cannabinoids, such as tetrahydrocannabinol, produce their biological effects through their interactions with cannabinoid receptors. The best-studied endogenous cannabinoids are 2-arachidonoyl glycerol and arachidonoyl ethanolamide (anandamide). Despite similarities in chemical structure, 2-arachidonoyl glycerol and anandamide are synthesized and degraded by distinct enzymatic pathways, which impart fundamentally different physiologic and pathophysiologic roles to these two endocannabinoids. As a result of the pervasive social use of cannabis and the involvement of endocannabinoids in a multitude of biological processes, much has been learned about the physiologic and pathophysiologic roles of the ECS. This review provides an introduction to the ECS with an emphasis on its role in synaptic plasticity and how the ECS is perturbed in schizophrenia.

Keywords: Cannabinoid; Cannabis; Lipid signaling; Retrograde messenger; Schizophrenia; Synaptic plasticity.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

All authors report no biomedical financial interests or potential conflicts of interest.

Figures

Fig. 1
Fig. 1. Overview of the localization of endocannabinoid system components at the synapse
Schematic of an inhibitory and excitatory terminal synapsing onto the dendritic shaft of a representative cortical principal neuron. Abbreviations: ABHD6, alpha/beta domain-containing hydrolase 6; CB1, CB1 cannabinoid receptor; CCK, cholecystokinin; COX-2, cyclooxygenase-2; DAGLα, diacylglycerol lipase α; M1, M1 muscarinic receptor; MAGL, monoacylglycerol lipase; mGluR5, metabotropic glutamate receptor 5; NAPE-PLD, N-arachidonoyl phosphatidyl ethanolamine-preferring phospholipase D; PLCβ, phospholipase C β. The increased number of CB1 receptors on the CCK/GABA terminal represents the higher density of CB1 receptors found on these axon terminals.
Fig. 2
Fig. 2. Potential synthetic and degradative pathways for anandamide and 2-AG
A. Primary synthetic pathways for anandamide. B. Primary degradative pathways for anandamide. C. Primary synthetic pathways for 2-AG. D. Primary degradative pathways for 2-AG. Only major pathways are shown. More comprehensive details can be found in recent reviews (–133). Abbreviations: AA, arachidonic acid; ABHD4, alpha/beta domain-containing hydrolase 4; ABHD6, alpha/beta domain-containing hydrolase 6; ABHD12, alpha/beta domain-containing hydrolase 12; COX-2, cyclooxygenase-2; DAG, diacylglycerol; DAGL, diacylglycerol lipase; FAAH, fatty acid aminohydrolase; GDE-1, glycerophosphodiesterase GDE-1; IP3, inositol tris-phosphate; LPA, lyso-phosphatidic acid; lyso-PLC, lyso-phospholipid-preferring phospholipase C; MAGL, monoacyl glycerol lipase; NAAA, N-acyl ethanolamine amino hydrolase; NAPE-PLD, N-arachidonoyl phosphatidyl ethanol-preferring phospholipase D; PIP2, phosphatidyl inositol bis-phosphate; Pi, PO4; PLA2, phospholipase A2; PLC, phospholipase C;
Fig. 3
Fig. 3. Forms of endocannabinoid-mediated synaptic plasticity and endocannabinoid mediated cell-autonomous regulation of excitability
A. Depolarization-induced suppression of excitation/inhibition. B. Metabotropic-induced suppression of excitation/inhibition. C. Homosynaptic and heterosynaptic long-term depression. D. Slow self inhibition. See text for details.

References

    1. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol. 2000;57:1045–1050. - PubMed
    1. Luk T, Jin W, Zvonok A, Lu D, Lin XZ, Chavkin C, et al. Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. Br J Pharmacol. 2004;142:495–500. - PMC - PubMed
    1. Mackie K, Devane WA, Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol. 1993;44:498–503. - PubMed
    1. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54:161–202. - PubMed
    1. Bae JS, Kim JY, Park BL, Kim JH, Kim B, Park CS, et al. Genetic association analysis of CNR1 and CNR2 polymorphisms with schizophrenia in a Korean population. Psychiatr Genet. 2014;24:225–229. - PubMed

Publication types

MeSH terms